Vitamin C and Vitamin E in Pregnant Women at Risk for Pre-eclampsia (VIP Trial): Randomized Placebo-Controlled Trial

Poston, Lucilla; Briley, Annette; Seed, Paul; Kelly, Frank J.; Shennan, AH

doi:10.1097/01.ogx.0000234632.66314.5e

Cited by 29 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, birth weight of newborns was lower whose mothers were taking vitamin E supplements. There is yet another study to support it (133). Collectively these studies suggest that use of antioxidant for prevention of eclampsia is not warranted.…”

Section: Antioxidant Therapy and Supplementsmentioning

confidence: 99%

Reactive oxygen species, reactive nitrogen species and antioxidants in etiopathogenesis of diabetes mellitus type-2

Singh

Mahadi

Roy

et al. 2009

Indian J Clin Biochem

View full text Add to dashboard Cite

Diabetes mellitus type-2 (DMT-2) is a hyperglycemic retinopathy and embryopathy) or a-vascular (cataract and glaucoma etc). It has been proposed that all these abnormal events are initiated or activated by a common mechanism of superoxide anion, which is accompanied with generation of a variety of reactive oxygen species (ROS), reactive nitrogen specie (RNS) and resultant heightened oxidative stress (OS). Provoked OS causes IR and altered gene expressions. Hyperglycemia induces OS through multiple routes : a)stimulated polyol pathway where in d 30% glucose can be diverted to sorbitol and fructose, b)increased transcription of genes for proinflammatory cytokines and plasminogen activator inhibitor-1 (PAI-1) c) activation of protein kinase-C (PKC) leading to several molecular changes d)increased synthesis of Advanced Glycation End Products (AGEs) e)changes in a receptor far AGEs and f) autooxidation of

show abstract

Section: Antioxidant Therapy and Supplementsmentioning

confidence: 99%

Reactive oxygen species, reactive nitrogen species and antioxidants in etiopathogenesis of diabetes mellitus type-2

Singh

Mahadi

Roy

et al. 2009

Indian J Clin Biochem

View full text Add to dashboard Cite

show abstract

“…For functional genomic studies to specifically address the influence of the strain background two papers were chosen that demonstrate the profound influence the genetic background has on the metabolic function and phenotype of a genetically modified organism (Hough et al 2002;Sam et al 2001). Finally a combination of clinical trials and studies of human metabolism where samples have been taken under less strict control of external variables were also considered (Brindle et al 2002;Poston et al 2006;Wolff et al 2004;Siu et al 2006;Townsley et al 2006;Khor et al 2006;Teahan et al 2006). These resultant reporting requirements were then compared with the information captured by other standards initiatives including MIAME (Minimum Information About a Microarray Experiment; Brazma et al 2001;Quackenbush 2004), (minimum information about a genome sequence (MIGS); http://www.genomics.ceh.ac.uk/genomecatalogue; Field et al 2006), CEBS and the human proteome organisation-proteomics standard initiative's (HuPO-PSI; minimum information about a proteomics experiment (MIAPE) ;Taylor 2006;Orchard et al 2003;Orchard et al 2005).…”

Section: The Analytical Process Used To Generate the Reporting Requirmentioning

confidence: 99%

Standard reporting requirements for biological samples in metabolomics experiments: mammalian/in vivo experiments

et al. 2007

View full text Add to dashboard Cite

With the increasing production of metabolomic data there is an awareness of a need for a standardised description of this data to aid assessment, exchange, storage and curation of information from metabolomic studies. In this manuscript the first draft of a minimum requirement for the description of the biological context of a metabolomic study involving mammalian subjects is described. This recommendation has been produced by the Metabolomics Standards Initiative-Mammalian Context Working Sub-Group (MSI-MCWSG) as part of the wider standardisation initiative led by the Metabolomics society. The experiments considered include functional genomic studies, drug toxicology, nutrigenomics, clinical trials, and other human studies. Two reporting requirements are described for pre-clinical (e.g. functional genomics, toxicology) and clinical (e.g. clinical trials, nutrigenomics) studies. It is planned that this will lead to the development of a tool for the description of metabolomic experiments that enables storage, retrieval and manipulation of large amounts of data. This will benefit the assessment and dissemination of metabolomic data from mammalian studies.

show abstract

“…Since 1994 had been encouraging results (20,30). This belief changed on March 2006, behind three studies (29,31,32) concluded that concomitant supplementation with vitamin C and vitamin E does not reduce the risk of preeclampsia, fetal or neonatal loss (2.6% versus 2.3%; RR 1.10; 95% CI 0.78-1.57), small for gestational age infant (20.6% versus 20%; RR 0.94; 95% CI These results do not support routine supplementation to prevent preeclampsia. However, Rumbold et al (29) consider these results cannot be generalized to women with low dietary intakes of antioxidants.…”

Section: Antioxidantsmentioning

confidence: 63%

Prediction and Prevention of Preeclampsia

Briceño-Pérez

Briceño-Sanabria

Gracia

2009

Hypertension in Pregnancy

View full text Add to dashboard Cite

Preeclampsia increases maternal and perinatal morbidity and mortality rates. Much research has been done to identify unique screening tests that would predict the risk of developing preeclampsia before the classic symptoms appear. The possible use of a screening test with high predictive accuracy in patients with high-risk or low-risk of preeclampsia remains to be investigated. At present, the search for additional tests continues. There is growing interest in the use of combinations of tests. Effective primary prevention is not possible because the causes are still unknown, but to identify and to modify susceptible risk factors might decrease the frequency of preeclampsia. A community guideline improves the screening and early detection of preeclampsia, and uniforms the referral thresholds and assessment procedures. Secondary prevention with calcium supplementation and aspirin administration during pregnancy are beneficial in low calcium intake women and in the patient at a very high risk of developing severe early onset disease. Lifestyle choices, dietary nutritional measures (antioxidant as vitamin C, vitamin E, lycopene, selenium, zinc, magnesium and the mitochondrial antioxidants nicotine, coenzyme Q(10) and melatonin; and other dietary nutritional measures as low dietary salt, omega 3 fatty acids, folic acid, garlic, nutritional advice, protein and energy supplementation, isocaloric balanced protein and protein and energy restriction for obese women) and others drugs; have not shown benefits or there is insufficient evidence to recommend clinical use. Proper antenatal care and timed delivery are of utmost importance in tertiary prevention.

show abstract

Vitamin C and Vitamin E in Pregnant Women at Risk for Pre-eclampsia (VIP Trial): Randomized Placebo-Controlled Trial

Cited by 29 publications

References 0 publications

Reactive oxygen species, reactive nitrogen species and antioxidants in etiopathogenesis of diabetes mellitus type-2

Reactive oxygen species, reactive nitrogen species and antioxidants in etiopathogenesis of diabetes mellitus type-2

Standard reporting requirements for biological samples in metabolomics experiments: mammalian/in vivo experiments

Prediction and Prevention of Preeclampsia

Contact Info

Product

Resources

About